Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Combination of Oral Lenalidomide and Low-dose Cyclophosphamide for Patients With Antibiotics-unresponsive Extranodal Marginal Zone B-cell Lymphoma

NCT04604028 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04604028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Combination of Oral Lenalidomide and Low-dose Cyclophosphamide for Patients With Antibiotics-unresponsive Extranodal Marginal Zone B-cell Lymphoma
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 10, 2020
Completion date
December 31, 2023
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotics-unresponsive malt lymphoma, refractory extranodal marginal zone b-cell lymphoma (malt), relapsed malt type extranodal marginal zone b-cell lymphoma